Empowered Patient Podcast

Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight.   Steffen elaborates, "What is understood now is obesity is the root cause of many sequel pathologies like type 2 diabetes, diabetes, fatty liver disease, and a whole lot of cardiovascular disease. So, the idea is that if we get obesity under control and the obesity pandemic under control, we might also lower the incidence of all the other diseases. There’s a massive rush into this field because there are already blockbuster drugs in th